Construction of vectors expressing bioactive heterodimeric and single-chain murine interleukin-12 for gene therapy

Yueh Lun Lee, M. I Hua Tao, Yen Hung Chow, Bor Luen Chiang

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

It has been well demonstrated that interleukin-12 (IL-12) could be useful to defend against a variety of pathogens, to suppress tumor growth and metastasis, and even to be employed as an adjuvant of vaccines to enhance beneficial type 1 T helper (Th1) cell response over detrimental type 2 T helper (Th2) cell responses. To apply IL-12 genes in gene therapy such as a DNA vaccine, a pIL-12 vector was constructed that contained two cytomegalovirus (CMV) promoters to drive the expression of p35 and p40 subunits, respectively. In addition, a pscIL-12 vector was designed with a linker to fuse p35 cDNA with p40 cDNA to produce a single-chain IL-12 protein, ensuring not only that the expression of p35 and p40 subunits was equally expressed, but also that no free p40 subunits interfered with IL-12 activity. The data suggested pIL-12 could produce a rather high level of biologically active IL-12 after transfection of COS cell lines as well as C2C12 muscle cell lines, as measured by both concanavalin A blast proliferation assay and enzyme-linked immunosorbent assay. Interestingly, the pscIL-12 vector could also express a bioactive murine IL-12 fusion protein in vitro. Furthermore, in vivo functional studies also demonstrated that mice co-immunized with a pS vector expressing the major envelope protein of hepatitis B virus (HBV) and IL-12 vectors encoding native IL-12 or single-chain IL-12 fusion protein elicited higher levels of IgG(2a) anti-HBs antibody and of Th1-related cytokine. Because p35 and p40 genes can be expressed in a vector by using a single promoter, pscIL-12 should be useful in future applications for nucleic acid vaccination or for gene therapy against diseases.

Original languageEnglish
Pages (from-to)457-465
Number of pages9
JournalHuman Gene Therapy
Volume9
Issue number4
Publication statusPublished - Mar 1 1998
Externally publishedYes

Fingerprint

Interleukin-12
Genetic Therapy
Helper-Inducer T-Lymphocytes
Complementary DNA
Cell Line
Th2 Cells
Th1 Cells
Proteins
DNA Vaccines
COS Cells
Concanavalin A
Cytomegalovirus
Hepatitis B virus
Muscle Cells
Nucleic Acids
Genes
Transfection
Anti-Idiotypic Antibodies
Vaccination
Vaccines

ASJC Scopus subject areas

  • Genetics

Cite this

Construction of vectors expressing bioactive heterodimeric and single-chain murine interleukin-12 for gene therapy. / Lee, Yueh Lun; Tao, M. I Hua; Chow, Yen Hung; Chiang, Bor Luen.

In: Human Gene Therapy, Vol. 9, No. 4, 01.03.1998, p. 457-465.

Research output: Contribution to journalArticle

Lee, Yueh Lun ; Tao, M. I Hua ; Chow, Yen Hung ; Chiang, Bor Luen. / Construction of vectors expressing bioactive heterodimeric and single-chain murine interleukin-12 for gene therapy. In: Human Gene Therapy. 1998 ; Vol. 9, No. 4. pp. 457-465.
@article{ae84dcbcd6314361b6470e9d4cdc2e99,
title = "Construction of vectors expressing bioactive heterodimeric and single-chain murine interleukin-12 for gene therapy",
abstract = "It has been well demonstrated that interleukin-12 (IL-12) could be useful to defend against a variety of pathogens, to suppress tumor growth and metastasis, and even to be employed as an adjuvant of vaccines to enhance beneficial type 1 T helper (Th1) cell response over detrimental type 2 T helper (Th2) cell responses. To apply IL-12 genes in gene therapy such as a DNA vaccine, a pIL-12 vector was constructed that contained two cytomegalovirus (CMV) promoters to drive the expression of p35 and p40 subunits, respectively. In addition, a pscIL-12 vector was designed with a linker to fuse p35 cDNA with p40 cDNA to produce a single-chain IL-12 protein, ensuring not only that the expression of p35 and p40 subunits was equally expressed, but also that no free p40 subunits interfered with IL-12 activity. The data suggested pIL-12 could produce a rather high level of biologically active IL-12 after transfection of COS cell lines as well as C2C12 muscle cell lines, as measured by both concanavalin A blast proliferation assay and enzyme-linked immunosorbent assay. Interestingly, the pscIL-12 vector could also express a bioactive murine IL-12 fusion protein in vitro. Furthermore, in vivo functional studies also demonstrated that mice co-immunized with a pS vector expressing the major envelope protein of hepatitis B virus (HBV) and IL-12 vectors encoding native IL-12 or single-chain IL-12 fusion protein elicited higher levels of IgG(2a) anti-HBs antibody and of Th1-related cytokine. Because p35 and p40 genes can be expressed in a vector by using a single promoter, pscIL-12 should be useful in future applications for nucleic acid vaccination or for gene therapy against diseases.",
author = "Lee, {Yueh Lun} and Tao, {M. I Hua} and Chow, {Yen Hung} and Chiang, {Bor Luen}",
year = "1998",
month = "3",
day = "1",
language = "English",
volume = "9",
pages = "457--465",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Construction of vectors expressing bioactive heterodimeric and single-chain murine interleukin-12 for gene therapy

AU - Lee, Yueh Lun

AU - Tao, M. I Hua

AU - Chow, Yen Hung

AU - Chiang, Bor Luen

PY - 1998/3/1

Y1 - 1998/3/1

N2 - It has been well demonstrated that interleukin-12 (IL-12) could be useful to defend against a variety of pathogens, to suppress tumor growth and metastasis, and even to be employed as an adjuvant of vaccines to enhance beneficial type 1 T helper (Th1) cell response over detrimental type 2 T helper (Th2) cell responses. To apply IL-12 genes in gene therapy such as a DNA vaccine, a pIL-12 vector was constructed that contained two cytomegalovirus (CMV) promoters to drive the expression of p35 and p40 subunits, respectively. In addition, a pscIL-12 vector was designed with a linker to fuse p35 cDNA with p40 cDNA to produce a single-chain IL-12 protein, ensuring not only that the expression of p35 and p40 subunits was equally expressed, but also that no free p40 subunits interfered with IL-12 activity. The data suggested pIL-12 could produce a rather high level of biologically active IL-12 after transfection of COS cell lines as well as C2C12 muscle cell lines, as measured by both concanavalin A blast proliferation assay and enzyme-linked immunosorbent assay. Interestingly, the pscIL-12 vector could also express a bioactive murine IL-12 fusion protein in vitro. Furthermore, in vivo functional studies also demonstrated that mice co-immunized with a pS vector expressing the major envelope protein of hepatitis B virus (HBV) and IL-12 vectors encoding native IL-12 or single-chain IL-12 fusion protein elicited higher levels of IgG(2a) anti-HBs antibody and of Th1-related cytokine. Because p35 and p40 genes can be expressed in a vector by using a single promoter, pscIL-12 should be useful in future applications for nucleic acid vaccination or for gene therapy against diseases.

AB - It has been well demonstrated that interleukin-12 (IL-12) could be useful to defend against a variety of pathogens, to suppress tumor growth and metastasis, and even to be employed as an adjuvant of vaccines to enhance beneficial type 1 T helper (Th1) cell response over detrimental type 2 T helper (Th2) cell responses. To apply IL-12 genes in gene therapy such as a DNA vaccine, a pIL-12 vector was constructed that contained two cytomegalovirus (CMV) promoters to drive the expression of p35 and p40 subunits, respectively. In addition, a pscIL-12 vector was designed with a linker to fuse p35 cDNA with p40 cDNA to produce a single-chain IL-12 protein, ensuring not only that the expression of p35 and p40 subunits was equally expressed, but also that no free p40 subunits interfered with IL-12 activity. The data suggested pIL-12 could produce a rather high level of biologically active IL-12 after transfection of COS cell lines as well as C2C12 muscle cell lines, as measured by both concanavalin A blast proliferation assay and enzyme-linked immunosorbent assay. Interestingly, the pscIL-12 vector could also express a bioactive murine IL-12 fusion protein in vitro. Furthermore, in vivo functional studies also demonstrated that mice co-immunized with a pS vector expressing the major envelope protein of hepatitis B virus (HBV) and IL-12 vectors encoding native IL-12 or single-chain IL-12 fusion protein elicited higher levels of IgG(2a) anti-HBs antibody and of Th1-related cytokine. Because p35 and p40 genes can be expressed in a vector by using a single promoter, pscIL-12 should be useful in future applications for nucleic acid vaccination or for gene therapy against diseases.

UR - http://www.scopus.com/inward/record.url?scp=0032032755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032032755&partnerID=8YFLogxK

M3 - Article

C2 - 9525307

AN - SCOPUS:0032032755

VL - 9

SP - 457

EP - 465

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 4

ER -